Details of the Drug

General Information of Drug (ID: DM2SQBF)

Drug Name
225Ac-labelled aCD33
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Drug Type
Radiopharmaceutical therapy agent
Cross-matching ID
TTD ID
DSI4G9

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloid cell surface antigen CD33 (CD33) DTT CD33 5.37E-13 0.58 1.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03705858) Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
2 Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.